Skip to main content

Table 4 Clinical characteristics for the identified DR candidates

From: Reversal gene expression assessment for drug repurposing, a case study of glioblastoma

Drug Candidates

Cluster ID

BBB

#Clinical Trials

FDA-Approved Indications

Temozolomide

8

0.9879

169

Glioblastoma multiforme, refractory anaplastic astrocytoma

Dasatinib

8, 3

0.507

5

Acute lymphoblastic leukemia; chronic myeloid leukemia

Sirolimus

8, 3

0.9599

5

Lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors

Etoposide

8

0.9609

5

Testicular and small cell lung tumors

Topotecan

8, 3

0.9659

3

Ovarian cancer, small cell lung cancer, or cervical cancer

Cabozantinib

8

Yes*

3

Advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer

Mitomycin

8

0.9659

3

Chemotherapeutic agent for various malignancies

Dacarbazine

8

0.9382

2

Malignant melanoma and Hodgkin's disease

Temsirolimus

8

0.9494

2

Renal cell carcinoma

Bortezomib

1

0.6533

2

Multiple myeloma

Axitinib

8

Yes*

2

Advanced renal cell carcinoma

Gemcitabine

8

0.9693

1

Adjunct therapy for ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer

Cytarabine

8

0.9465

1

Acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia

Romidepsin

8

Yes*

1

Cutaneous T-cell lymphoma

Simvastatin

8

0.9422

1#

Lower lipid levels and reduce the risk of cardiovascular events

Docetaxel

8

Poor*

1#

Locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, head and neck cancer

Thalidomide

8

0.9382

1

Newly diagnosed multiple myeloma, erythema nodosum leprosum

Epirubicin hydrochloride

8

0.9951

1#

Axillary node metastases in patients of primary breast cancer

Tigecycline

8

0.9836

0

Bacterial infections

Podofilox

8

0.5388

0

External genital warts and perianal warts

Prochlorperazine

8

0.9781

0

Schizophrenia and anxiety and to relieve severe nausea and vomiting

Clofarabine

8

0.9827

0

Relapsed or refractory acute lymphoblastic leukemia

Ciclopirox

8

0.9892

0

Mild to moderate onychomycosis of fingernails and toenails in immunocompetent patients

Tacrolimus

8

0.9659

0

Prevent organ transplant rejection and to treat moderate to severe atopic dermatitis

  1. BBBs are the Blood–Brain Barrier permeability probabilities obtained from the Drugbank database, and * indicates that the BBB were obtained from published studies as they were missing in the Drugbank database. The column of Clinical Trials lists the number of GBM related clinical trials registered in ClinicalTrials.gov, and # indicates that the clinical trials were identified via literature review. The column of Approved Indications lists the drugs' FDA-approved indications obtained from the Drugbank database